AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Eledon Pharmaceuticals, Inc.
Video analysis: ELDN
All videosNo video analysis for this stock yet. Request one from our team.
News: ELDN
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026.
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant Company on track to initiate global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in Q4 2026 IRVINE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced significant progress across multiple tegoprubart development programs in kidney allotransplantation and islet cell transplantation.
647,812 Shares in Eledon Pharmaceuticals, Inc. $ELDN Acquired by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 647,812 shares of the company's stock, valued at approximately $2,552,000. ADAR1 Capital Management LLC owned 0.84% of Eledon
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026 IRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2026 operating and financial results and provided recent business highlights.
Eledon: At The Center Of The Next Medical Frontier
Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in kidney transplantation and significant undervaluation versus risk-adjusted fair value. Tegoprubart targets kidney transplants, Type 1 Diabetes islet cell transplants, and ALS, with potential multi-billion dollar annual revenue if approved and established. Despite reliance on a single asset, ELDN's risk-adjusted fair value is $11.69 per share, over triple the current price, even after conservative success probabilities.
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of tegoprubart, an in.
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
